Status of New Vaccine Introduction - Worldwide, 2016-2021

MMWR Morb Mortal Wkly Rep. 2023 Jul 7;72(27):746-750. doi: 10.15585/mmwr.mm7227a2.

Abstract

This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. By 2021, among 194 countries worldwide, 33 (17%) provided all of these 10 WHO-recommended antigens as part of their routine immunization schedules; only one low-income country had introduced all of these recommended vaccines. Universal hepatitis B birth dose; human papillomavirus vaccine; rotavirus vaccine; and diphtheria, tetanus, and pertussis-containing vaccine first booster dose have been introduced by 57%, 59%, 60%, and 72% of all countries worldwide, respectively. Pneumococcal conjugate vaccine, rubella-containing vaccine, measles-containing vaccine second dose, and Haemophilus influenzae type b vaccine have been introduced by 78%, 89%, 94%, and 99% of all countries, respectively. The annual rate of new vaccine introductions declined precipitously when the COVID-19 pandemic started, from 48 in 2019 to 15 in 2020 before rising to 26 in 2021. Increased efforts to accelerate new and underutilized vaccine introductions are urgently needed to improve universal equitable access to all recommended vaccines to achieve the global Immunization Agenda 2021-2030 (IA2030) targets.

MeSH terms

  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines*
  • Hepatitis B Vaccines
  • Humans
  • Immunization Schedule
  • Infant
  • Measles Vaccine
  • Pandemics
  • Poliovirus Vaccine, Inactivated
  • Rubella Vaccine
  • Vaccination
  • Vaccines, Combined

Substances

  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines
  • Measles Vaccine
  • Rubella Vaccine
  • Poliovirus Vaccine, Inactivated
  • Hepatitis B Vaccines
  • Vaccines, Combined